本季度信息
瑛泰医疗披露的2026年中期报告显示，期内实现营收5.96亿元，同比提升29.28%。期内整体毛利为3.64亿元，同比提升34.63%，毛利率从上年同期的58.70%上升至61.13%。经调整净利润录得1.26亿元，较上年同期的1.02亿元增长22.68%。经营活动所得净现金流为2.12亿元，相较上年同期的1.23亿元大幅提升72.86%。
从成本结构上来看，销售及分销相关费用为0.73亿元，同比上升76.27%；占总营收比重为12.28%，上年同期占比为9.01%。管理费用为0.88亿元，同比提升36.06%。研发投入从上年同期的0.92亿元增加至1.03亿元，占营收比重保持相对稳定。
业务分项
介入医疗器械业务在报告期内实现收入5.34亿元，同比增长36.07%。代理业务收入为0.19亿元，同比下降41.59%。管理层指出，介入医疗器械的高增长主要受并购与自身产品矩阵构建的带动。
高管解读
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.